Production of Recombinant Factor VIII in Human Cell Lines.
Sign Up to like & getrecommendations! Published in 2018 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-7312-5_5
Abstract: Human cell lines can produce recombinant proteins much more similar to their natural counterpart, compared to other mammalian cell lines, reducing potential immunogenic reactions. Recombinant proteins produced in nonhuman cells can have in its structure… read more here.
Keywords: cell lines; recombinant factor; human cell; cell ... See more keywords
The intraoperative use of recombinant activated factor VII in arterial switch operations.
Sign Up to like & getrecommendations! Published in 2020 at "Cardiology in the young"
DOI: 10.1017/s1047951120004072
Abstract: BACKGROUND The rate of bleeding complications following arterial switch operation is too low to independently justify a prospective randomised study for benefit from recombinant factor VIIa. We aimed to evaluate factor VIIa in a pilot… read more here.
Keywords: study; arterial switch; factor; factor viia ... See more keywords
Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Clinical and Laboratory Investigation"
DOI: 10.1080/00365513.2022.2040048
Abstract: Abstract The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients… read more here.
Keywords: complex concentrate; fibrinogen concentrate; concentrate; recombinant factor ... See more keywords
Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering
Sign Up to like & getrecommendations! Published in 2022 at "Critical Reviews in Biotechnology"
DOI: 10.1080/07388551.2022.2036691
Abstract: Abstract Appropriate treatment of Hemophilia B is vital for patients’ quality of life. Historically, the treatment used was the administration of coagulation Factor IX derived from human plasma. Advancements in recombinant technologies allowed Factor IX… read more here.
Keywords: recombinant factor; bioprocessing cell; factor; production ... See more keywords
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2115777
Abstract: Abstract Background and objective A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. Methods The model was based on 100 patients from the… read more here.
Keywords: recombinant factor; without inhibitors; cost; emicizumab ... See more keywords
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14152
Abstract: In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B. read more here.
Keywords: recombinant factor; extended dosing; protein rfixfc; factor fusion ... See more keywords
Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14493
Abstract: The large interpatient variability in the pharmacokinetic (PK) parameters of recombinant Factor VIII (rFVIII) observed in haemophilia A hinders efficient and cost‐beneficial prophylactic regimen initiation. Identification of factors influencing the PK of rFVIII may shed… read more here.
Keywords: influence blood; recombinant factor; blood group; haemophilia influence ... See more keywords
The structural basis for the functional comparability of factor VIII and the long‐acting variant recombinant factor VIII Fc fusion protein
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13700
Abstract: Essentials Recombinant factor VIII (rFVIII) Fc fusion protein has a 1.5‐fold longer half‐life than rFVIII. Five orthogonal methods were used to characterize the structure of rFVIIIFc compared to rFVIII. The C‐terminal Fc fusion does not… read more here.
Keywords: factor; recombinant factor; factor viii; fusion protein ... See more keywords
Safety first: Tracking adverse events associated with new therapies for people with hemophilia
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15188
Abstract: The year 1992 was momentous for individuals affected by hemophilia. Eight years after the successful cloning of the factor VIII gene and 5 years after clinical trials assessing the safety and efficacy of recombinant factor… read more here.
Keywords: recombinant factor; safety; factor viii; food drug ... See more keywords
Recombinant Factor VIIa–Mediated Activation of Prothrombin Complex Concentrates
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/1076029616663848
Abstract: Recombinant factor VIIa (rFVIIa) is used in the management of bleeding in patients with hemophilia. A generic biosimilar version of NovoSeven is also developed (AryoSeven). To compare the activation profile of NovoSeven and AryoSeven, 2… read more here.
Keywords: factor viia; recombinant factor; prothrombin; activation ... See more keywords
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/1076029620946839
Abstract: Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonacog gamma (BAX… read more here.
Keywords: nonacog gamma; recombinant factor; previously treated; hemophilia ... See more keywords